Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

2.220 +0.030 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Via ACCESS Newswire
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Via ACCESS Newswire
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Top movers in Wednesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Via ACCESS Newswire
Ensysce Biosciences Issues Annual Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Via ACCESSWIRE
Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why
Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protection technology. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Via ACCESS Newswire
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled
The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed. 
Via Stocktwits
Topics Government
Exposures Political
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Via ACCESS Newswire
Ensysce Biosciences Regains Full Compliance with Nasdaq
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.